Production (Stage)
OptimizeRx Corporation
OPRX
$12.19
-$0.45-3.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.66% | 28.81% | 40.40% | 35.15% | 26.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.66% | 28.81% | 40.40% | 35.15% | 26.71% |
| Cost of Revenue | 10.84% | 14.42% | 30.40% | 29.58% | 30.37% |
| Gross Profit | 26.95% | 38.41% | 47.14% | 38.82% | 24.47% |
| SG&A Expenses | 6.48% | 14.06% | 12.63% | 12.08% | 7.65% |
| Depreciation & Amortization | 44.91% | 80.15% | 128.99% | 90.08% | 49.23% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.26% | 16.06% | 21.04% | 19.45% | 15.62% |
| Operating Income | 70.47% | 52.96% | 53.44% | 39.01% | 28.28% |
| Income Before Tax | 36.28% | 22.87% | -143.00% | -83.37% | -79.66% |
| Income Tax Expenses | 90.25% | 109.58% | -27,854.55% | -25,378.79% | -- |
| Earnings from Continuing Operations | 14.71% | -14.48% | -75.81% | -24.82% | -28.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.71% | -14.48% | -75.81% | -24.82% | -28.36% |
| EBIT | 70.47% | 52.96% | 53.44% | 39.01% | 28.28% |
| EBITDA | 112.43% | 82.54% | 75.16% | 55.31% | 39.61% |
| EPS Basic | 18.36% | -7.51% | -64.13% | -20.87% | -28.64% |
| Normalized Basic EPS | 32.41% | 7.91% | 14.11% | 11.62% | 12.99% |
| EPS Diluted | 18.67% | -6.97% | -65.46% | -21.91% | -29.67% |
| Normalized Diluted EPS | 32.41% | 7.91% | 14.11% | 11.62% | 12.99% |
| Average Basic Shares Outstanding | 5.60% | 6.82% | 6.85% | 2.34% | -1.10% |
| Average Diluted Shares Outstanding | 5.60% | 6.82% | 6.85% | 2.34% | -1.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |